Cowie, Biodesix CFO, sells $6834 in BDSX stock
Robin Harper Cowie, CFO of Biodesix (NASDAQ:BDSX), sold 535 shares of the company's common stock for approximately $6,834 on February 23, 2026. This transaction occurred after Cowie also exercised options to acquire 1,469 shares via restricted stock units on February 20, 2026. The sale comes as Biodesix shares have seen an 87.79% year-to-date surge, despite the company remaining unprofitable in the last twelve months, though recent preliminary Q4 and full-year 2025 results show significant revenue growth and EBITDA profitability.
How this was made

The 30-second read
Why it matters
While insider sales can sometimes precede negative developments, in this case, the sale's modest size and the company's positive financial indicators suggest limited impact.
Market read
The event has limited immediate trading relevance but warrants ongoing monitoring for insider activity trends.
What to watch
The company's recent revenue growth and EBITDA profitability indicate underlying strength; insider sales should be contextualized within broader financial performance.
Background
Cowie, as CFO, sold a small portion of her holdings amid a significant share price increase, which could reflect personal liquidity needs or strategic diversification.
Ticker impact
The insider sale by Cowie, CFO of Biodesix, indicates potential insider sentiment but is limited in scope and magnitude.
Minimal short-term impact; potential slight bearish bias if viewed as profit-taking, but unlikely to influence stock trajectory significantly.
The small volume of insider sale relative to total shares and the company's overall positive revenue trend suggest limited immediate impact. However, insider sales can sometimes signal caution, warranting monitoring.
Market effects
The biotech and life sciences sectors may experience minor volatility due to insider trading activities, but this event alone is unlikely to cause sector-wide shifts.
Limited regional impact; confined to the company's primary market and investor base.
Negligible
Counterpoint
The insider sale could be a routine profit-taking event with no bearing on company fundamentals, suggesting no change in investment stance.
Key entities
- CompanyBiodesix
A biotech company specializing in diagnostics and life sciences.


